| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $289,295 | 2 | 13 |
Sells | $66,864,161 | 13 | 87 |
| MCCOLLUM JAMES W | director | 1 | $239,278 | 0 | $0 | $239,278 |
| Chevallard Daniel R. | Chief Financial Officer | 1 | $50,017 | 0 | $0 | $50,017 |
| Olsson Shawn | Chief Commercial Officer | 0 | $0 | 1 | $261,022 | $-261,022 |
| Versant Venture Capital VI, L.P. | 10 percent owner | 0 | $0 | 12 | $66.6M | $-66.6M |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Over the last 12 months, insiders at LENZ Therapeutics, Inc. have bought $289,295 and sold $66.86M worth of LENZ Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at LENZ Therapeutics, Inc. have bought $7.92M and sold $66.86M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MCCOLLUM JAMES W (director) — $239,278. Chevallard Daniel R. (Chief Financial Officer) — $50,017.
The last purchase of 10,500 shares for transaction amount of $239,278 was made by MCCOLLUM JAMES W (director) on 2025‑11‑07.
| 2025-11-17 | Sale | Olsson Shawn | Chief Commercial Officer | 10,000 0.0552% | $26.10 | $261,022 | -34.40% | |
| 2025-11-07 | MCCOLLUM JAMES W | director | 10,500 0.0506% | $22.79 | $239,278 | -25.84% | ||
| 2025-11-07 | Chevallard Daniel R. | Chief Financial Officer | 2,198 0.0106% | $22.76 | $50,017 | -25.84% | ||
| 2025-09-30 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 224,974 2.191% | $46.01 | $10.35M | -56.93% | |
| 2025-09-18 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 135,304 1.2095% | $42.23 | $5.71M | -44.91% | |
| 2025-08-26 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 70,811 0.5847% | $39.01 | $2.76M | -31.55% | |
| 2025-08-25 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 78,237 0.6548% | $39.54 | $3.09M | -33.34% | |
| 2025-08-22 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 39,046 0.3318% | $40.15 | $1.57M | -33.83% | |
| 2025-08-18 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 45,713 0.3731% | $38.56 | $1.76M | -31.09% | |
| 2025-08-15 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 215,000 1.7975% | $39.50 | $8.49M | -29.41% | |
| 2025-07-10 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 191,376 1.3772% | $34.00 | $6.51M | -12.78% | |
| 2025-06-27 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 200,000 1.2896% | $30.46 | $6.09M | -0.03% | |
| 2025-06-20 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 234,801 1.5054% | $30.29 | $7.11M | +0.67% | |
| 2025-06-18 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 100,000 0.6339% | $29.95 | $3M | +0.27% | |
| 2025-06-10 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 350,000 2.1483% | $29.00 | $10.15M | +6.84% | |
| 2024-05-14 | Chevallard Daniel R. | Chief Financial Officer | 3,188 0.0106% | $15.68 | $49,988 | |||
| 2024-05-13 | MCCOLLUM JAMES W | director | 31,332 0.1061% | $15.99 | $501,093 | |||
| 2024-03-21 | RA CAPITAL MANAGEMENT, L.P. | 998,009 3.1748% | $15.03 | $15M |
| Increased Positions | 102 | +50.75% | 13M | +45.26% |
| Decreased Positions | 89 | -44.28% | 7M | -24.9% |
| New Positions | 49 | New | 5M | New |
| Sold Out Positions | 56 | Sold Out | 6M | Sold Out |
| Total Postitions | 214 | +6.47% | 35M | +20.35% |